Navigation Links
Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
Date:4/27/2012

HAMPTON, Va., April 27, 2012 /PRNewswire-USNewswire/ -- Patient Advocate Foundation (PAF) announced today its formation of a new Electrolyte Imbalance Silo within its Co-Pay Relief (CPR) program. This new CPR program silo will provide financial support for pharmaceutical co-payments to insured patients facing clinically significant electrolyte imbalance related health problems. "Electrolyte imbalance can pose an urgent threat to a patient and can become quite serious if left untreated," said Nancy Davenport-Ennis, founder and CEO of PAF. "We are grateful for this contribution which will allow us to expand our Co-Pay Relief Program to provide financial support to patients in need ensuring access to the treatments that can restore balance to their health and markedly improve their quality of life."

Since PAF's Co-Pay Relief program was founded in 2004, it has provided more than $150 million in financial assistance to more than 68,000 patients who would have been otherwise unable to afford their pharmaceutical co-payments. The program provides this support to insured patients, including those covered by Medicare Part D, who financially and medically qualify.  Its disease and treatment silos cover 15 categories, including: Breast Cancer, Chemotherapy Induced Neutropenia, Colon Cancer, Cutaneous  T-Cell Lymphoma, Hepatitis C, Hormone Suppression Therapy, Electrolyte Imbalance, Non-Small Cell Lung Cancers, Multiple Myeloma, Myelodysplastic Syndrome (and other pre-leukemia diseases), Non Muscle Invasive Bladder Cancer, Osteoporosis, Pain, Rheumatoid Arthritis and Sarcoma. 

For more information about PAF's Co-Pay Relief program, visit www.copays.org or call 866-512-3861.

About the Patient Advocate Foundation (PAF) Co-Pay Relief Program (CPR)
The Co-Pay Relief Program provides direct financial support for pharmaceutical co-payments to insured patients who financially and medically qualify.

The program offers innovative technology tools for patients, providers and pharmacy representatives including 24 hour web based application portals, electronic signature, document upload and bar code fax routing capabilities, increasing the speed with which an approval can be granted and expenditure can be paid.  Keeping with Patient Advocate Foundation's emphasis on excellent patient service, the program also offers individualized service to all patients through the use of call counselors; personally guiding them through the enrollment process.  

For more information or to contact the Co-Pay Relief program visit www.copays.org or 1-866-512-3861


'/>"/>
SOURCE Patient Advocate Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
2. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
3. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
4. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
5. Phreesia identifies over 26% of patients who require additional autism evaluation
6. Watching, Reading and Listening: A New Way to Interact with Patient Information
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
9. New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients
10. Phase 2b Study of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
11. Genetic testing for new warfarin patients is rare, but often inappropriate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016  Increasingly, health care professionals are enhancing patient ... wireless technology. With the Vios Monitoring System from Vios ... remotely detect problems before they become serious by continuously ... the United States . ... --> The Vios Monitoring System connects ...
(Date:2/9/2016)... Feb. 9, 2016  Johnson & Johnson (NYSE: ... Global Healthcare Conference on Tuesday, Feb. 23, at the ... Caruso , Vice President, Finance & Chief Financial Officer ... represent the Company in a session scheduled at 10:00 ... --> www.investor.jnj.com . --> This webcast ...
(Date:2/9/2016)... , Feb. 9, 2016 Athenex, Inc. announced ... as Vice President of Corporate Strategy and Business Development based ... MBA has joined as Senior Director and Deputy Head of Clinical Research ... . Simon Pedder stated, "Athenex has a ... a while. Coupled together with their unique business model and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over ... of Medicare Part D a decade ago, according to The Senior Citizens League ... on how they are coping with rapidly rising costs. “The implications are chilling, ...
(Date:2/10/2016)... ... February 09, 2016 , ... According to a recent ... dramatic increase in the number of patients under the age of 30. According to ... seeing in their offices, and may indicate an overall shift in the rapidly growing ...
(Date:2/9/2016)... Nevada (PRWEB) , ... February 09, 2016 , ... ... providing treatment to Medicaid beneficiaries who are diagnosed with autism spectrum disorder (ASD). ... Nevada. Autism treatment using applied behavior analysis (ABA) is key to providing ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... compensation fee schedule rates and Medicare rates for a variety of medical services ... report, Evaluation of the 2015 Fee Schedule Rates in Illinois, are ...
(Date:2/9/2016)... NY (PRWEB) , ... February 09, 2016 , ... Establishment ... appointment of Dr. David Hung to the company´s Board of Directors. , ... world class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of ...
Breaking Medicine News(10 mins):